XML 41 R34.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies - Schedule of significant segment expenses (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]                
Total operating expenses $ 19,070     $ 20,510     $ 61,767 $ 45,881
Loss from operations (19,070)     (20,510)     (61,767) (45,881)
Other income, net 1,047     1,042     3,680 2,485
Change in fair value of warrant liabilities 564     96,439     22,917 51,829
Net income (loss) (17,459) $ (11,216) $ (6,495) 76,971 $ (44,907) $ (23,631) (35,170) 8,433
Operating Segments [Member]                
Segment Reporting Information [Line Items]                
Tegoprubart - kidney transplantation programs 9,363     10,167     26,600 19,284
Tegoprubart - other development programs       14     (168) 430
Manufacturing 1,736     4,252     11,031 7,826
Personnel-related 3,664     2,524     10,808 7,400
Stock-based compensation 2,428     1,783     7,986 6,540
Other operating expenses 1,879     1,770     5,510 4,401
Total operating expenses 19,070     20,510     61,767 45,881
Loss from operations (19,070)     (20,510)     (61,767) (45,881)
Other income, net 1,047     1,042     3,680 2,485
Change in fair value of warrant liabilities 564     96,439     22,917 51,829
Net income (loss) $ (17,459)     $ 76,971     $ (35,170) $ 8,433